ArticleMetabolomics : Official journal of the Metabolomic Society2025
Urinary metabolites associated with the long-term risk for chronic kidney disease incidence and progression in hypertensive patients.
Article in Metabolomics : Official journal of the Metabolomic Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundHypertension is a leading risk factor for chronic kidney disease (CKD), yet the metabolic mechanisms linking hypertension to CKD remain unclear. This study aimed to identify metabolites associated with CKD incidence and progression in hypertensive patients using untargeted metabolomics analysis.
methodsA prospective cohort study was conducted to identify metabolites associated with the incidence and progression of CKD in hypertensive patients. Untargeted metabolomic profiling was conducted, and three statistical models-logistic regression, lasso regression, and random forest-were utilized to identify metabolites associated with CKD. Modified Poisson regression was used to assess the associations between metabolites and kidney-related outcomes.
resultsUntargeted metabolomic profiling identified distinct metabolite patterns distinguishing hypertensive patients with CKD from those without. These metabolites were identified across the three statistical models, with 94 showing significance in at least two. Four metabolites-L-theanine, cysteine-s-sulfate, mesaconic acid, and 2-aminoadipic acid-were inversely associated with CKD incidence and progression. L-theanine and cysteine-s-sulfate were both associated with decreased estimated glomerular filtration rate (eGFR) and increased urinary albumin-to-creatinine ratio (UACR). In contrast, mesaconic acid was linked to increased UACR, and 2-aminoadipic acid was associated with decreased eGFR. Patients at higher risk of CKD progression exhibited significantly lower levels of these metabolites.
conclusionL-theanine, cysteine-s-sulfate, mesaconic acid, and 2-aminoadipic acid show an inverse association with CKD incidence and progression in hypertensive patients, suggesting their potential as biomarkers for CKD risk. Further studies are warranted to validate these findings and investigate their therapeutic implications.
Indexed as
Identifiers
41003842What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.